Every material Form 8-K Iambic Therapeutics, Inc. has filed with the SEC since October 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Iambic Therapeutics filed an amended and restated certificate of incorporation and adopted amended and restated bylaws on October 16, 2026, in connection with completing its initial public offering. The filing refers to the prospectus filed October 15, 2026 for the full description of the new governing documents, which set out the company's shareholder framework now in effect.
Restated Certificate of Incorporation filed with Delaware Secretary of State on October 16, 2026, tied to the IPO completion
Restated Bylaws adopted effective October 16, 2026, described in the October 15, 2026 final prospectus
Item 7.01 notes the company may use its website, social media and other channels to disclose material information
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Iambic Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →